Background Through delayed HIV disease progression, highly active antiretroviral therapy (HAART) may reduce direct medical costs, thus at least partially offsetting therapy costs. Recent findings regarding the secondary preventive benefits of HAART necessitate careful consideration of funding allocations for HIV/AIDS care. Our objective is to estimate non-HAART direct medical costs at different levels of disease progression and over time in British Columbia, Canada. Methods We considered the population of individuals with HIV/AIDS within a set of linked disease registries and health administrative databases (N = 11,836) from 1996 to 2010. Costs of hospitalization, physician billing, diagnostic testing and non-HAART medications were calculated in 2010 Canadian dollars. Effects of covariates on quarterly costs were assessed with a two-part model with logit for probability of non-zero costs and a generalized linear model (GLM). Net effects of CD4 strata on direct non-HAART medical costs were evaluated over time during the study period. . Hospitalization comprised the majority of the increment in costs amongst those with no measured CD4. Evaluated at CD4 state conditional means, those with CD4 \200/mm 3 incurred quarterly costs of Can$5,781 (95 % CI 4,846) versus Can$1,307 (95 % CI 1,460; p \ 0.001) for CD4 C500/mm 3 in 2010. Conclusion Non-HAART direct medical costs were substantially lower for individuals during periods of sustained virologic suppression and high CD4 count. HIV treatment and prevention evaluations require detailed health resource use data to inform funding allocation decisions.
Key Points for Decision Makers
Studies capturing direct medical costs for HIVpositive individuals prior to HAART initiation are rare. Evaluated at CD4 state conditional means, we found direct medical costs prior to HAART initiation were similar to those of individuals with CD4 [500/ mm 3 .
Non-HAART direct medical costs were 3.4 times greater during periods with CD4 cell counts below 200/mm 3 compared with those with CD4 [500/ mm 3 , with much of the difference comprising hospitalization costs.
Introduction
Sustained adherence to highly active antiretroviral therapy (HAART) stops viral replication, promotes immune reconstitution, prevents disease progression and prolongs survival [1, 2] . As a result, HAART has been documented to decrease the incidence of episodes of acute care, thus reducing health resource utilization and offsetting the costs of antiretroviral medications [3] [4] [5] .
Evidence for the secondary preventive effect of HAART on HIV transmission [6] has spawned efforts to scale-up HIV treatment programs globally [7] . In turn, this has spurred further epidemiological and economic modeling efforts to project outcomes of various HIV treatment and prevention strategies [5, [8] [9] [10] [11] to inform optimal use of scarce healthcare resources. In British Columbia (BC), Canada, under the auspices of the Ministry of Health, the BC Centre for Excellence in HIV/AIDS (BC-CfE) partnered with a consortium of provincial healthcare partners to implement the Seek and Treat for Optimal Prevention of HIV and AIDS (STOP HIV & AIDS) pilot project [12] .
The majority of HIV transmission models employed in cost-effectiveness analyses model disease progression via transitions between health states defined by CD4 strata [11, [13] [14] [15] . Recent systematic reviews of published HIV costing studies revealed only nine studies that provided adequate cost data, and valid comparisons of total direct medical costs between studies were not possible because of differences in the specific components included, the heterogeneous nature of study populations in terms of disease stage, the sources and methods used to estimate unit costs, and the level of aggregation at which results were reported [16, 17] . Further, many of these studies were based on preand early-HAART era patient populations. Given the substantial innovations in antiretroviral treatment and subsequent changes in therapeutic guidelines, it is likely that individuals more recently diagnosed and initiating treatment using modern regimens follow substantially different trajectories of health resource use, with potentially important implications in health resource allocation decisions.
Perhaps most importantly, however, none of the reviewed studies captured direct medical costs for individuals before initiating HAART. Given the transmissibility of HIV/AIDS, adequately capturing health and economic benefits to interventions requires mathematical models that capture HIV transmission explicitly; inclusion of those not yet accessing HIV treatment is necessary as these individuals disproportionately drive HIV transmission. We take advantage of a unique linked populationlevel dataset that captures health resource utilization for individuals linked to HIV care (i.e., receiving HIV diagnostic testing or antiretroviral treatment), as well as periods prior to linkage for those entering HIV care to characterize and quantify health resource use for this under-researched population [18] .
From a methodological standpoint, there has been substantial debate regarding appropriate practices for modeling healthcare costs [19] [20] [21] [22] [23] . This revolves around the nonnormal distribution of individual-level healthcare costs, which are typically characterized by a nontrivial fraction of zero outcomes among repeated measurements, non-negative measurements of the outcomes, and a positively skewed empirical distribution of the non-zero realizations. Each of these problems precludes the use of standard linear models and demand careful consideration of the modeling strategy. Therefore, our objective is to longitudinally characterize direct non-HAART medical costs through stages of linkage to care and disease progression for HIVinfected individuals in BC, Canada throughout the HAART era.
Methods

Subjects
This study was based on a provincial-level linkage of a set of seven health administrative databases and disease registries, including the BC-CfE drug treatment program and virology registries (antiretroviral dispensations, plasma viral load [pVL] and CD4 tests), the BC Centre for Disease Control HIV testing database (HIV diagnosis), the Medical Services Plan database (physician billing records), the discharge abstract database (hospitalizations), the BC PharmaNet database (non-antiretroviral drug dispensations) and the BC Vital statistics database (deaths). We considered all individuals identified as HIV positive within this set of databases from 1 January, 1996 to 31 March, 2010. Further details regarding the construction of the cohort and available databases have previously been described [18] . For each individual, quarterly data was available from the point of HIV diagnosis to death, administrative loss to follow-up or censorship (ongoing care as of 30 March, 2010). We chose a quarterly timeframe to mirror evidence-based CD4 and pVL monitoring guidelines, as per the International Antiviral Society-USA (IAS-USA) guidelines [24] . Administrative loss was defined as no records in any of the linked databases for a period of at least 18 months.
The study cohort was followed in a unique environment characterized by universal free medical care, including free in-and out-patient care, laboratory monitoring, and antiretroviral drugs. pVL data capture in the BC-CfE registries are complete for the population of individuals with HIV/ AIDS in the province, and CD4 cell count data capture has previously been estimated at 80 % [25] .
Dependent Variables
The primary dependent variables considered in these analyses were direct non-HAART medical costs, and their components: costs of hospitalization, physician billing, and non-HAART drug dispensations. Costs of HAART were excluded from this analysis as these patient-level costs follow a different process, influenced more by technological development of antiretroviral medications and changes in clinical practice guidelines and less by disease progression [5, 26] .
Costs of physician billings as well as medication dispensations, including pharmacy dispensation costs, were derived directly from the BC MSP (Medical Services Plan) and BC PharmaNet datasets, respectively. The BC MSP is an itemized schedule of reimbursement fees for the full range of medical services; therefore, they represent average costs of producing care from a third-party payer perspective. The costs of inpatient care were estimated by multiplying hospital resource intensity weights, collected throughout the province and study period, by an estimated cost per weighted case (CWC) for the province of British Columbia in 2010 [27] . CWC is based on standard methodologies developed by the Canadian Institution of Health Information (CIHI), and is used across Canada in the analysis of hospital services [28] . Case-mix group costings, similar to diagnostic-related group costings in the US, are used by healthcare funding organizations to judge intensity of service utilization and to make subsequent funding decisions [28] . Finally, non-HAART costs of medical care were calculated as the sum of the costs of hospitalizations, physician claims, non-HAART medication dispensations and diagnostic testing, including CD4, pVL and resistance testing. For the latter, counts of CD4, pVL and resistance tests were multiplied by unit costs derived from the BC Center for Disease Control (BCCDC) and BC-CfE. All costs were adjusted for inflation using the Canadian Consumer Price Index [29] and presented in 2010 Canadian dollars (Can$).
Independent Variables
As determinants of the set of defined study outcomes, we considered both fixed and time-varying effects of demographic indicators, clinical stage and access to treatment. Patient demographics included age, gender and temporal period of HIV diagnosis (pre-1996; 1996-1999; 2000-2003; post-2003) . Medical comorbidity was captured using the Charlson Comorbidity Index (CCI) score, indicating the level of medical comorbidity from ICD-9/10 codes in hospitalizations in the prior year. The CCI is a weighted comorbidity score ranking 22 conditions by disease severity (individual conditions are given a weight of 1-6 points according to the risk of mortality) on a negative, continuous scale [30] . Illicit drug use status was defined as ever having any illicit drug-related service delivered (including drug-related inpatient and outpatient care, as indicated by a previously defined set of ICD-9/10 codes [31] , opioid substitution treatment dispensations in the BC PharmaNet database, or other addiction services, captured in the BC Addiction Information Management Systems Database. We also included linear and quadratic time trend variables.
Indicators of clinical stage included CD4 cell count at initial measurement, current CD4 cell count (including CD4 measurements within 6 months of the earliest date in a given quarter) across five strata (C500/mm 3 ; 350-499/ mm 3 ; 200-349/mm 3 ; \200/mm 3 ; CD4 unmeasured), and the area under the log 10 (pVL) curve (AUC pVL) in the year of the quarterly observation, stratified into five categories: (C3.5; 3-3.49; 2.7-2.99; \2.7; AUC pVL unmeasured). As pVL and CD4 measures are known to have independent effects on AIDS-related illness and mortality [32, 33] , time-varying effects for each measure were included. AUC values were used only for pVL measurements due primarily to their volatility; this measure was found to be a more sensitive indicator of disease severity than the most recent pVL measurement [34] . AUC pVL strata corresponded to sustained log 10 pVL \2.7 (pVL \500 copies per mL); 3.0 (pVL \1,000 copies per mL) and 3.5 (pVL \3,500 copies per mL) over a 12-month period and were chosen based on the empirical distribution in the data. CD4 strata were chosen for clinical significance and their historic use as treatment initiation thresholds in IAS-USA guidelines [24] . Following linkage to HIV care (with linkage to care defined as the first receipt of HIV diagnostic test (CD4 or pVL) following diagnosis), we executed a multiple imputation procedure to impute values in quarters with missing AUC pVL or CD4 measures. A time-varying indicator of HAART receipt captured whether antiretroviral medication was received during the person-quarter. While CD4 and pVL may be considered intermediates in the causal pathway between HAART and non-HAART medical costs, we included this covariate to capture additional variation attributable to HAART receipt, which could be considered an indicator of engagement with the healthcare system.
The study population included individuals unlinked to HIV care for some period of follow-up or throughout follow-up. We included the 'unmeasured' CD4 and AUC pVL categories to allow for direct comparison of health resource use with the various stages of disease progression following linkage to care. In a supplemental analysis focusing on observations prior to linkage to HIV care, we compare those unlinked to HIV care throughout follow-up with those eventually linking to HIV care.
Statistical Analysis
Two-part, or hurdle models were estimated to account for excess zeroes in each of the selected dependent variables. In the first stage, generalized linear models were specified with binomial distributions and logit link functions [22] . In the second stage, modified Park tests were executed to determine the appropriate distributional family [35] . Models were initially estimated with gamma distribution and log link function. Huber-White standard errors were calculated to control for intra-individual correlation in repeated measurements in the generalized linear models [36, 37] .
Finally, following a previous application [38] , we used the product rule to determine the total marginal effects of CD4 strata on the set of defined dependent variables. Specifically, total costs (TC) were modeled as the product of two factors (TC = P 9 L), where P is the probability of having non-zero costs and L is the level of the non-zero costs that occur. The 2-step procedure generates separate estimates of the marginal effects of CD4 strata on each factor, which we call P 0 (CD4) and L 0 (CD4), respectively. To generate an estimate of the overall effect on costs of a change in CD4, we apply the product rule of calculus to derive TC
. We interpret TC 0 (CD4) as the marginal effect on total costs of a change in CD4 stratum. Marginal effects for L and P were evaluated at the mean value of all covariates. We subsequently estimate mean quarterly stratum-specific non-HA-ART medical costs by calendar year throughout the study period, evaluated both at unconditional population-level mean-valued covariates, and CD4 stratum and calendar year-specific mean-valued covariates. The model was estimated using the tpm procedure and margins post-estimation command in STATA. Robust standard errors for the combined marginal effects of covariates on total costs were estimated using the delta method [39] .
Results
Our study population comprised 11,836 individuals identified as HIV positive with at least two quarters of observation, 2,785 (23.5 %) of whom never accessed HAART during study follow-up. The mean duration of follow-up was 7.3 person-years overall (4.6 for those never accessing HAART, and 8.1 for those ever accessing HAART). A total of 2,883 individuals died during study follow-up, while another 448 were administratively lost to follow-up. As a result, 8,505 (71.9 %) remained in the study at the end of study follow-up.
Summary statistics on the study population, direct non-HAART medical costs and their components are detailed in Table 1 . The mean age of the population at HIV diagnosis was 38.8 (SD 11.0), 19.6 % were female, and 45.6 % had accessed health services for substance abuse at some point during follow-up. Nearly 53 % of the sample were diagnosed before 1999, 25 % had no baseline CD4 measurement, and 42.5 % had no baseline pVL measurement. All cost outcomes were highly skewed, and mean estimates were heavily influenced by outlying observations. The hospitalization cost outcome was most frequently equal to zero (91.4 %), while total costs were zero in 10.7 % of all person-quarters of observation. Among non-zero observations, mean total costs were Can Results of the two-stage analysis on direct non-HAART medical costs are presented in Table 2 . Marginal effects on the probability of non-zero costs in a given observation period and costs in non-zero observations are presented. Female gender, older age, high levels of medical comorbidity (CCI scores) and ever having accessed health services for substance abuse were all statistically significantly associated with higher direct non-HAART medical costs. Costs were substantially higher in observations within 3 months of mortality, and quarters in which individuals were receiving HAART. Those with extended durations of unsuppressed pVL (indicated by AUC pVL) also incurred higher quarterly costs. Finally, lower current CD4 cell counts were statistically significantly associated with progressively higher direct non-HAART medical costs, while observations prior to linkage to HIV care (CD4 unmeasured) were also associated with higher costs compared with periods of CD4 [500/mm 3 . The net effects of current CD4 and AUC pVL stratum on direct non-HAART medical costs (based on mean- valued covariates over the complete follow-up period), estimated using the product rule as detailed in the methods section above, are presented in Fig. 1 3 . A subsequent analysis focusing on durations of follow-up prior to linkage to HIV care found that those unlinked throughout follow-up incurred quarterly costs that were not statistically significantly different from those linking to care during follow-up (pre-linked vs unlinked: -Can$54.07; p = 0.429; results available in Table A3 of the electronic supplementary material [ESM] ).
The net effects of current CD4 stratum on direct non-HAART medical costs are decomposed in Table 3 (complete sets of marginal effects from which these estimates were drawn are presented in Table A1 of the ESM). Compared with person-quarters with CD4 C500/mm 3 , those with no available CD4 data (i.e., prior to linkage to HIV care) incurred similar non-HAART drug dispensation costs (-Can$22 [-52 to 8], but substantially higher costs of hospitalization Can$341 [267-416]) and higher physician billing costs as well (Can$47 ); the increment in hospitalization and physician billing costs among those with no available CD4 data were lower than the CD4 \200/mm 3 stratum, but higher than the CD4 200-349/mm 3 stratum. Finally, Fig. 2 presents estimated mean quarterly costs by CD4 stratum over time, with estimates evaluated at unconditional mean-valued covariates and mean-valued covariates conditional on calendar year and CD4 stratum. Further, higher costs were only observed in quarters in which individuals were at more advanced stages of disease progression (CD4 \350/mm 3 ); quarterly costs were stable or declined for each of the other CD4 strata (quarterly means and confidence intervals are presented in Table A2 of the ESM). Finally, using observed distributions of covariates observed for those prior to HIV care linkage, the unmeasured CD4 stratum was not statistically significantly different from the CD4 C500/mm Table A3 of the ESM).
Discussion
Using population-level data on a population-based cohort of HIV-positive individuals accessing and not accessing HA-ART within a fully subsidized universal healthcare system, we estimated direct non-HAART costs of medical care. Our results showed that among HIV-positive individuals, periods with high CD4 counts and sustained virologic suppression were associated with substantially lower costs of medical care, due primarily to lower hospitalization costs. Quarterly costs were highest within the final 3 months before mortality, and when accessing HAART, an indicator of optimal engagement in HIV care which likely also represents unmeasured factors that lead to HAART prescription, rather than the direct effect of HAART prescription on non-HA-ART medical costs.
While the independent effect of being unlinked to HIV care was statistically significantly greater than the CD4 [500/mm 3 group, conditional mean costs (fitted values conditional on CD4 state-specific covariates) were similar to periods with CD4 [500/mm 3 , a result likely driven by earlier (unmeasured) stages of disease progression prior to linkage to HIV care, and an important distinction for future economic modeling efforts in HIV/ AIDS. It is important to note uncontrolled HIV due to poor engagement in HIV care and not being able to access HAART in particular results in the natural course of HIV, resulting in mortality within 10 years of infection [32] . HAART was long considered cost effective due to the substantial improvements in the duration and quality of life, even before the secondary preventive benefits of treatment were considered [40] ; our results on the costs of care for individuals not linked to HIV care should thus be interpreted in the appropriate context. The relationships between CD4, pVL and non-HAART medical costs have not always been clearly understood and articulated in past analyses, in part because these are commonly combined with the costs of HAART [16, 17, 40] . Further, little is known regarding the costs medical care for HIV-infected individuals prior to linkage to HIV care and subsequent access to HAART, yet it is important to capture these costs in modeling efforts to inform HA-ART scale-up. Primary care costs have previously been positively related to disease progression, as later disease stage may necessitate closer physician monitoring and carries a higher probability of inpatient care due to the occurrence of opportunistic infections, adverse drug reactions and related medical complications [3, 4, 40] . Our findings are consistent with these prior studies, and suggest those not accessing regular HIV care incur healthcare costs similar to those with low CD4 cell counts.
Our study has also revealed important distinctions in HAART and non-HAART direct medical costs. A previous analysis articulated the relationship between CD4, pVL and the direct costs of HAART [26] . In this study, individuals with sustained virologic suppression tended to have higher treatment costs, controlling for other factors, while those with high CD4 counts tended to have modestly lower drug treatment costs. High CD4 counts are often indicative of early stages of disease progression, whereas sustained virologic suppression (and thus low pVL AUC values) may be obtained at any stage of disease progression, with appropriate use of HAART (often requiring switches to more costly regimens due to the emergence of intolerance or viral resistance) to achieve and sustain suppression. In contrast, sustained virologic suppression, along with higher CD4 counts, were both associated with lower quarterly costs of medical care, consistent with the notion that successful medical management of HIV with HAART can offset the costs of primary care. The distinctions between HAART and non-HAART medical costs are critical to accurately model the economic impact of HIV treatment and prevention efforts.
Otherwise, our results on non-HAART medical costs were highly consistent with at least two prior US-based studies on the costs of HIV/AIDS. Reporting on a study based on the nationwide HIV Research Network, Gebo et al. [41] reported mean non-HAART medical costs of A B Fig. 2 Quarterly non-HAART medical costs by CD4 stratum (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) [42] (all figures adjusted to 2010 US dollars). In contrast, a prior study on a Canadian sample, followed up from 1997 to 2006, found similarly increasing non-HAART costs by CD4 stratum, though the levels of costs were lower, with quarterly costs of Can$709 for CD4 [500/mm 3 , Can$932 for CD4 201-500/mm 3 , and Can$2,712 for CD4 \200/mm 3 in 2006 [43] (all costs presented in 2010 Canadian dollars). This disparity is at least partially explained by the substantially higher proportion of injection drug users in the present analysis; however, further analysis into disparities in HIV care and practice patterns across Canada are called for. Nonetheless, our results appear to be externally valid, with a perhaps surprising degree of consistency in health resource use patterns with US-based studies that was not unduly affected by healthcare setting.
This analysis has several limitations. First, while the study was based on a population-level registry of antiretroviral treatment dispensation, initiated in 1992 (in the pre-HAART era), and despite similarities to prior findings in US-based studies, caution must be exercised in applying these estimates to other settings given the characteristics of clients, the nature of the HIV epidemic in BC, healthcare delivery policies and current and historical factor prices. If sufficient data is not available, extrapolation using the regression models, and based on localized population and policy conditions, with some adjustment for differential factor prices, may reduce bias. Second, current CD4 and pVL measurements were not always available in all time periods following HAART initiation; a multiple imputation scheme approach was used to impute missing observations. Also, CD4 cell counts have been noted to exhibit considerable variability as a result of intra-person temporal fluctuation (e.g., diurnal variation) as well as from measurement error [44] . This measurement error is likely to be non-differential, leading to measures of association being attenuated towards the null hypothesis. Finally, like all non-experimental studies, our coefficient estimates may have been subject to some degree of bias as a result of unmeasured confounding factors [45] .
Conclusion
To conclude, we found that non-HAART direct medical costs were substantially lower for individuals during periods of sustained virologic suppression and high CD4 count.
Our results demonstrate that administrative data are an essential source of information for studies of the financial burden of disease. These databases can be significantly augmented by linkage to disease registries to the benefit of economic modeling efforts to inform policy and practice.
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